Brief: Kamada And Kedrion Biopharma Announce Global Collaboration For The Development, Manufacturing And Distribution Of A Plasma-Derived Anti-Sars-Cov-2 (Covid-19) Polyclonal Immunoglobulin Product
27/04/2020 12:49
April 27 (Reuters) - Kamada Ltd KMDA.TA :
* KAMADA AND KEDRION BIOPHARMA ANNOUNCE GLOBAL COLLABORATION
FOR
THE DEVELOPMENT, MANUFACTURING AND DISTRIBUTION OF A
PLASMA-DERIVED ANTI-SARS-COV-2 (COVID-19) POLYCLONAL
IMMUNOGLOBULIN PRODUCT
* KAMADA- RESPONSIBLE FOR PRODUCT DEV, MANUFACTURING,
CLINICAL
DEVELOPMENT, REGULATORY SUBMISSIONS, DISTRIBUTION IN TERRITORIES
NOT UNDER KEDRION
Source text for Eikon: ID:nGNXLBPJr
Further company coverage: KMDA.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kamada
See all newsBrief: Kamada Updates On Withholding Tax Procedures On Previously Announced Cash Dividend To Shareholders
Brief: Kamada Announces Planned Transition Of Chief Financial Officer
Brief: Kamada Q2 EPS USD 0.16
Brief: Kamada Announces FDA Approval Of Its New In-House Rabies Virus Neutralization Testing Laboratory
Brief: Kamada Q4 EPS USD 0.06